

Sample B: CIRM CLINICAL PROTOCOL SYNOPSIS TEMPLATE

STUDY TITLE
<i>Provide full title of the study</i>
CLINICAL PHASE
<i>Specify clinical phase (1, 2a)</i>
STUDY OBJECTIVES
<i>Provide a brief description of the study objectives e.g., why is the study being done, what is the intent? E.g., safety, feasibility</i> <i>Primary Objectives:</i> <i>Secondary Objectives:</i> <i>Exploratory Objectives:</i>
STUDY RATIONALE
<i>Summarize the rationale for testing the proposed therapy</i>
STUDY POPULATION
<i>Briefly describe the study population and explain the rationale for choosing this population</i>
MAIN INCLUSION/EXCLUSION CRITERIA
<i>Specify the main inclusion/exclusion criteria and explain the rationale.</i>
PRIMARY ENDPOINT (S)
<i>Describe the Primary Endpoint(s) and the set of measurements used to address the objectives</i>
SECONDARY & EXPLORATORY ENDPOINTS
<i>Describe the Secondary & Exploratory Endpoint(s) and measures that will address them</i>
STUDY DESIGN
<i>Summarize the study design, including type of study, number of arms, controls or comparators</i>
SUBJECT NUMBER
<i>Provide the total number of study subjects, the number per study arm, and justification</i>
TREATMENT DURATION
<i>Specify the length of the treatment period</i>
DURATION OF FOLLOW UP
<i>Specify the length of the protocol-specified follow up period</i>

DOSE LEVEL (S) AND DOSE JUSTIFICATION
<i>Specify the dose level(s), number of doses, and dosing frequency. Summarize how dosing was determined</i>
ROUTE OF DELIVERY
<i>Specify how the doses will be delivered</i>
DATA and SAFETY MONITORING PLAN (DSMP)
<i>Summarize the Data and Safety Monitoring Plan. Describe measures that will be implemented to minimize risk to study subjects e.g. specific inclusions/exclusions; plans to ensure medical intervention in the case of an adverse event for subjects; plans for surveillance, detection and management of specific adverse events that might or could occur; potential use of an Independent Safety Monitor or Data Safety Monitoring Board (DSMB)</i>
STOPPING RULES
<i>Specify stopping rules</i>
IMMUNE MONITORING & IMMUNOSUPPRESSION
<i>Describe and justify the plan for immunosuppression and immune monitoring (if applicable)</i>
SUPPORTING STUDIES
<i>Summarize supporting studies that are part of this clinical study (e.g. imaging, biomarker analyses, cell phenotyping, genotyping, gene expression analyses), that will provide critical additional data to address the objectives of this RFA or inform decisions on continued clinical testing. Include:</i> <i>Objectives and rationale</i> <i>Sample collections (specify type, frequency)</i> <i>Testing methodology</i> <i>Data analysis</i> <i>Special considerations</i>
ASSAYS/METHODOLOGIES
<i>Briefly describe any specialized assays or methodologies that will be used in this clinical study or supporting study/studies. (Provide a more detailed summary of assay methods and summarize assay qualification/validation in Part D). Indicate where specialized testing will be conducted</i>
STATISTICAL ANALYSIS PLAN
<i>Summarize the Statistical Analysis Plan or describe how the data will be analyzed</i>
OUTCOME CRITERIA
<i>Describe criteria that would define whether you would or would not move forward with the subsequent development plan, based upon primary and designated secondary objectives</i>

RISKS
<i>Identify potential risks and mitigation strategies (e.g. need for and risks associated with long term immunosuppression)</i>
CLINICAL SITES
<i>Indicate the number of clinical sites that will participate in the study. Summarize the criteria for site selection. Provide a list of proposed sites with a brief description of the site's experience and capabilities in the conduct of clinical research.</i>
CLINICAL OPERATIONS PLAN
<i>Summarize the plan for managing the conduct of the clinical study. Describe plans for training clinical investigators and personnel at clinical sites and the plan for oversight and monitoring of clinical sites. Indicate who will be responsible for management and sign off of clinical operations activities.</i>
ENROLLMENT
<i>Describe the enrollment strategy and provide a timeline showing enrollment projections Describe plans for inclusion of women and minorities</i>
LONG TERM FOLLOW UP
<i>Describe requirements and plans for long term follow up and indicate how these will be supported</i>
TIMELINE
<i>Provide a timeline for completion of the study and indicate relevant milestones</i>